During the past decade, The Hong Kong Cancer Institute conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "The Hong Kong Cancer Institute" are "Anaplastic Gliomas" (1 trials), "Glioblastoma Multiforme" (1 trials), "Glioblastoma by Gene Expression Profile" (1 trials), "Glioma of Brain" (1 trials) and "Gliosarcoma" (1 trials). Many other conditions were trialed in "The Hong Kong Cancer Institute" in a lesser frequency.

Most popular intervention types in "The Hong Kong Cancer Institute" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Axitinib 1 MG" (1 trials), "Pazopanib 5 MG" (1 trials), "Sunitinib 5 MG" (1 trials) and "pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Hong Kong Cancer Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "The Hong Kong Cancer Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in The Hong Kong Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Hong Kong Cancer Institute, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".